[pivaloyl-14 C]S-1108, which is 14 C labeled at the pivalic acid moiety of the pivaloyloxymethyl side chain of S-1108, was administered orally to rats and dogs, and the disposition of pivalic acid cleft from S-1108 was examined. Besides pivaloylcarnitine and pivaloylglucuronide, pivaloylglycine was identified in dog urine as a metabolite of pivalic acid by thin-layer chromatography and high-performance liquid chromatography analysis. The concentrations in the plasma of rats to which doses of 6.65, 26.6, and 532 mg/kg of body weight were administered showed dose-proportionate levels. The radioactivity was eliminated rapidly, with a half-life of approximately 3 h until 24 h at both the 6.65-and 26.6-mg/kg doses. Free pivalic acid in plasma accounted for more than 80% of the concentration of radioactivity. Radioactivity was distributed throughout the body and was eliminated quickly at a rate similar to that of radioactivity from plasma. Most of the absorbed radioactivity was excreted in the urine, and it was completed within 24 h after administration. In dogs, the half-life of radioactivity in plasma was longer than that in the rats. The ratio of free pivalic acid in plasma was 60 to 70% of the radioactivity in plasma. The concentration of radioactivity in the liver, cortex of the kidney, and skeletal muscle 144 h after oral dosing was more than 10 times higher than the concentration in plasma for all doses. Urinary excretion in dogs was slower than that in rats. The differences in the disposition of pivalic acid between dogs and rats may account for differences in the degree of skeletal muscle disorders. The safety in humans of S-1108 given at 200 mg three times a day is discussed in relation to the metabolic formation of the carnitine conjugate of pivalic acid and the reduction of the carnitine concentration in plasma.
C at the thiazole moiety at the C-7 position of the cephem ring, and unlabeled S-1108 by microbiological assay (14) . Furthermore, studies of the metabolic disposition of formaldehyde generated from POM have been performed by using [methylene- 14 C]S-1108, which is labeled with 14 C at the methylene moiety of the POM side chain (23) .
Some antibiotics with a POM ester such as pivampicillin, pivmecillinam (amdinocillin pivoxil), and cefteram pivoxil have already been used to treat infectious diseases. Recently, administration of POM ester-type antibiotics, especially longterm administration, has been demonstrated to give rise to myopathic carnitine deficiency because of carnitine consumption by pivalic acid (9) . Vicker et al. (30) found that pivaloylcarnitine and pivaloylglucuronide are the metabolites of pivalic acid in the urine of humans and monkeys following administration of the pivaloyloxyethyl ester of methyldopa. Furthermore, the formation of pivaloylcarnitine following pivampicillin administration has been reported (15, 16) . Despite the strong attention focused on the effect of pivalic acid on the carnitine level (2, 9, 10, 15, 16) , there have been no reports about the general disposition of pivalic acid in relation to its safety and toxicity characteristics.
In the study described here [pivaloyl- 14 C]S-1108 was administered to rats and dogs, and the metabolic disposition of pivalic acid was examined to elucidate the biological characteristics of pivalic acid and to obtain information for assessing the safety of S-1108 in humans.
MATERIALS AND METHODS
Compounds. [pivaloyl- 14 C]S-1108, which was labeled with 14 C at the pivalic acid moiety of the POM side chain, was synthesized by reaction of S-1006 sodium salt with [ 14 C]iodomethyl pivalate prepared from t-butyl chloride and 14 CO 2 , as illustrated in Fig. 1 . The specific activity of the compound was 1,076 kBq/mg for the rats (for the suspended formulation) and 7.35, 150, and 1,093 kBq/mg for the dogs (for powder in a capsule), and the radiochemical purity was more than 96%.
[1-
14
C]pivaloylglycine and [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] C]pivaloylcarnitine hydrochloride were synthesized by a reaction of [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] C]pivaloylchloride with glycine and carnitine, respectively, as illustrated in Fig. 2 . The specific activities were 1.06 and 1.03 MBq/mg, respectively, and radiochemical purities were 98.8 and more than 99%, respectively.
Animals. Male Sprague-Dawley rats (ages, 8 to 9 weeks; weights, 270 to 330 g; CLEA Japan Inc., Tokyo, Japan) and male beagle dogs (ages, 10 months; weights, 10 to 11 kg; Aburahi Laboratory, Shionogi & Co. Ltd.) were used.
Drug administration. [pivaloyl- 14 C]S-1108 was administered at doses of 6.65 mg (11 mol) per kg of body weight, 26.6 mg (44 mol) per kg, and 532 mg (880 mol) per kg to both rats and dogs. These doses correspond to 5, 20, and 400 mg of S-1006 per kg, respectively.
(i) Rats. The dose formulation for rats was made by suspending [pivaloyl- 14 C]S-1108 and unlabeled S-1108 in a 0.5% methylcellulose solution at concentrations of 3.33, 13.3, and 266 mg/ml. Rats were administered the [pivaloyl- 14 C]S-1108 formulation orally at one of the doses given above by using a disposable flexible stomach tube (RZ-2; CLEA Japan Inc.).
(ii) Dogs. The dose formulation for dogs was made by packing the correct amount of [pivaloyl- 14 C]S-1108 in a size 00 gelatin capsule (Japan Elanko, Co., Ltd., Osaka, Japan) for the 6.65-mg/kg dose, a size 000 gelatin capsule for the 26.6-mg/kg dose, and a size 11 (1/2-oz. [ca. 14-g]) capsule (Kasyo Co., Ltd., Tokyo, Japan) for the 532-mg/kg dose. The capsule was administered orally with 10 ml of water at 10 a.m. Ten minutes after the administration, the dogs were fed.
Blood sampling. (i) Rats. A polyethylene tube (PE-50; Clay Adams, Parsipany, N.J.), on the tip of which a 5-mm silicone tube (0.025 in. [0.06 cm; inner diameter] by 0.47 in. [1.2 cm; inner diameter]; Medical-Grade Tubing; Dow Corning, Midland, Mich.) was attached, was inserted into the jugular veins of rats under ether anesthesia by the method of Upton (29) , and the rats were placed in plastic cages individually on the day before dosing. On the next day, the rats were administered the [pivaloyl- 14 C]S-1108 formulation orally and blood (0.25 ml) was withdrawn from the cannula at predetermined times.
(ii) Dogs. Dogs were administered [pivaloyl- 14 C]S-1108 as a capsule formulation, and blood (1.5 ml) was withdrawn from the saphenous vein of the foreleg at predetermined times.
Collection of urine and feces. (i) Rats. Rats were placed in Bollman cages (KN-326; Natsume Seisakusho Co., Ltd., Tokyo, Japan), and the urine and feces were collected at predetermined times.
(ii) Dogs. The urine, which was withdrawn from the urinary bladder through a Neraton catheter (Sherwood, Mo.) (size, 8 Fr.) or discharged spontaneously, was collected at the prescribed times. At each collection, the urinary bladder was rinsed with 5 ml of saline two times, and these washings were combined with the urine. The feces were collected daily until 144 h after administration. Tissue sampling. (i) Rats. The rats used for determination of drug levels in tissue were administered [pivaloyl- 14 C]S-1108 and were anesthetized with ether and killed by withdrawing blood from the abdominal aorta at the predetermined time. The following tissue and organs were dissected: submaxillary gland, lymph node (neck), thyroid, thymus, lung, heart, spleen, lever, pancreas, fat (perirenal), adrenal, kidney, testis, skeletal muscle, bone marrow, skin, brain, and hypophysis.
(ii) Dogs. Dogs were anesthetized by injecting 0.5 ml of pentobarbital sodium (Nembutal; Dainippon Pharmaceutical Co., Ltd., Osaka, Japan) per kg and were killed at 144 h after drug administration by withdrawing blood from the catheter which was inserted into the carotid aorta. The following tissue and organs were dissected: lung, heart, spleen, pancreas, fat, adrenal, testis, and skeletal muscle.
Measurement of radioactivity. An aliquot of plasma, urine, and dichloromethane extract was taken into a vial and weighed precisely. Then, 10 ml of scintillation cocktail (PICO-FLUOR 40; Packard, Downers Grove, Ill.) was added and the radioactivity in the vial was measured with a liquid scintillation spectrometer. The feces was diluted with an appropriate amount of water and was homogenized with a Polytron apparatus (PT-20; KINEMATICA GmbH, Lucerne, Switzerland) to make it a homogeneous slurry. After measuring the total amount of fecal slurry, a part of the slurry (200 to 400 mg) was taken into a vial, and 1 ml of solubilizer (SOLUENE-350; Packard) and 0.2 ml of perchloric acid solution (31%) were added. After being left overnight, 10 ml of scintillation cocktail was added to a vial and the radioactivity was measured. An entire organ (in the case of a small organ) or a part of a tissue or an organ was placed in the vial and weighed precisely. It was combusted in an oxidizer (model 306-C; Packard); this was followed by trapping the 14 CO 2 in 9 ml of CARBO-SORB (Packard) and mixing 11 ml of PERMA-FLUOR V scintillation cocktail (Packard), and the sample was assayed by the same method used to assay the feces. The metabolites separated by thin-layer chromatography (TLC) were scraped off the plate and were placed in a vial; this was followed by the addition of 1 ml of methanol and 10 ml of PICO-FLUOR 40.
Radioactivity measurements were made in a liquid scintillation spectrometer (Tri-Carb 2000CA; Packard). All counts were corrected for quenching by the external standardization method.
Separation of conjugated metabolites in urine. An aliquot of urine was spotted onto a TLC plate (silica gel 60 F 254 , precoated, 0.25-mm thick; E. Merck AG, Darmstadt, Germany), and the plate was developed with the following solvent system: ethyl acetate-acetic acid-H 2 O (4:1:1; by volume). After development, the plate was dried completely with hot air. The spots of metabolites were scraped off the plate, and the radioactivity was measured. The separation of conjugated metabolites was also performed by a high-performance liquid chromatography (HPLC) method by using a Shimadzu LC-6A pump. Urine samples were separated with a Nucleosil 10 C 18 column (4.6 by 300 mm) with a mobile phase of 5 mM PIC A (Waters)-CH 3 CN (90:10) at a flow rate of 1.0 ml/min, and radioactivity was detected by using a radiodetector (RAMONA-90, Raytest; Straubenhardt, Germany) radiodetector.
Hydrolysis of glucuronic acid conjugate of pivalic acid. ␤-Glucuronidase solution (13,000 units/ml; Tokyo Zoki Co., Ltd., Tokyo, Japan) was added to 1 ml of urine, collected during the 8 to 12 h after oral administration of 26.6 mg of [pivaloyl- 14 C]S-1108 per kg to dogs, and the mixture was incubated for overnight at 37ЊC. After the completion of incubation, the urine sample was subjected to the TLC separation. In the alkaline hydrolysis procedure, 1 ml of urine was added to 1 ml of 2 N NaOH, and the mixture was left to stand for 30 min. Then, the mixture was neutralized with 6 N HCl and subjected to the TLC separation as described above.
Determination of free pivalic acid. Accurately weighed urine and plasma, approximately 0.5 ml in volume, were adjusted to pH 2 with 0.3 N HCl, and were then extracted with 5 ml of dichloromethane three times. After weighing the total dichloromethane extract, a part of its extract was weighed precisely and its radioactivity was measured.
Pharmacokinetic analysis of data. Biological half-lives (t 1/2 ) of the concentration (radioactivity) in plasma were determined by the least-squares method from the log-linear portion of the curves that were obtained. The total area under the plasma concentration (radioactivity)-time curve (AUC) from time zero to the last determination time was calculated by the trapezoidal rule. The time of maximum concentration (T max ) is given as a mean value for all animals.
RESULTS

Identification of metabolites of pivalic acid in dog urine.
The urine obtained from 8 to 12 h after oral administration of [pivaloyl-
14 C]S-1108 was analyzed by TLC to detect and identify the metabolites.
Three radioactive spots (M-1, M-2, and M-3) were found to be urinary metabolites, as shown in Fig. 3A . Among them, M-1 and M-3 were identified as pivaloylcarnitine and pivaloylglycine, respectively, because their R f values coincided with those of the respective authentic compounds.
The TLC profile of M-2 after ␤-glucuronidase and NaOH hydroxylation are indicated in Fig. 3B and C, respectively. Spot M-2 disappeared by ␤-glucuronidase hydrolysis and an alter- native spot, spot M-4, appeared (Fig. 3B ). On the other hand, spots M-1 and M-2 disappeared completely by NaOH hydrolysis ( Fig. 3C ). Therefore, it was concluded that spot M-2 was the glucuronide of pivalic acid. The new spot M-4 was suspected of being a ␤-glucuronidase-resistant glucuronide generated from M-2 by intramolecular rearrangement. It was very difficult to detect free pivalic acid on the TLC plates, because free pivalic acid is developed at nearly the solvent front and is easily volatilized from there. Figure 4 shows the HPLC profiles of urinary metabolites in the dog detected by measuring radioactivity, and the retention times of the metabolites are compared with those of radioactive authentic metabolites.
As Fig. 4 shows, there are four metabolites (P-1, P-3, P-4, and P-5) other than free pivalic acid (P-2). P-1 and P-3 were also identified as pivaloylcarnitine and pivaloylglycine, respectively, by comparison of the retention times with those of the authentic samples. Although conclusive evidence has not been obtained, P-4 and P-5 was considered to be the glucuronide of pivalic acid and its rearrangement product, respectively, from the results of TLC surveillance described above.
Disposition of pivalic acid from [pivaloyl- Figure 5 shows the concentration of radioactivity in plasma after oral administration of [pivaloyl- 14 C]S-1108 at three doses. The maximum concentrations of radioactivity (C max s) after administration of doses of 6.65, 26.6, and 532 mg/kg were 9.14, 40.13, and 867.4 nmol/ml, respectively; thus, a dose-proportionate concentration was obtained. The time to reach C max (T max ) became longer with increasing dose, and the t 1/2 s of the elimination phase (during 1 to 24 h at the dose of 6.65 mg/kg, 2 to 48 h at the dose of 26.6 mg/kg, and 12 to 72 h at the dose of 532 mg/kg) were 2.8, 3.4, and 5.3 h, respectively. Although the t 1/2 became slightly longer with increasing dose, these differences did not appear to be significant.
C]S-1108 in rats. (i) Concentration in plasma.
The proportion of free pivalic acid made up more than 80% of the concentration of radioactivity in plasma. In particular, at the 532-mg/kg dose it exhibited the highest ratio (more than 90% [data not shown]).
(ii) Distribution in tissue. Table 1 provides the concentration of radioactivity in tissue after oral administration of [pivaloyl- 14 C]S-1108 at three doses. After administration of the dose of 6.65 mg/kg, the concentrations of radioactivity in most tissues and organs except for the kidney and heart were the highest at 1 h after administration. This suggests that the absorption of the pivalic acid generated from S-1108 is very fast. At 1 and 4 h after administration, the highest concentrations of radioactivity were found in the kidney and liver, and high concentrations were observed in the plasma, blood, heart, lung, and adrenal. Concentrations in the fat, testis, bone marrow, brain, and hypophysis were low, and those in the skeletal muscle were also low. At 24 h after administration, the concentrations in most tissues were extremely low.
After administration of the dose of 26.6 mg/kg, the peak concentrations in most tissues were found 1 h after administration, but those in the heart, liver, and kidney were observed 4 h after administration. The concentrations in most tissues at 1 h were approximately four times higher than those obtained after administration of the dose of 6.65 mg/kg. The rank of the concentration in tissue after administration of the dose of 26.6 mg/kg was similar to that after administration of the dose of 6.65 mg/kg, and the concentration in the skeletal muscle was low. These levels decreased to less than 2 nmol/g at 24 h and to extremely low levels 72 h after administration.
After administration of the dose of 532 mg/kg, the concentration of radioactivity peaked 10 h after administration, and the values were 20 to 30 times higher than those obtained after administration of the dose of 26.6 mg/kg. The order of the concentration in tissue after administration of the dose of 532 mg/kg was similar to those obtained after administration of the lower doses, and the elimination of radioactivity from the tissues was also as rapid as that in the experiments with lower doses.
(iii) Excretion. Table 2 provides the urinary and fecal excretion of radioactivity after oral administration of [pivaloyl- 14 C]S-1108 at the three doses. Excretion of radioactivity into urine was fast after administration of the dose of 6.65 mg/kg, so the cumulative excretion up to 6, 24, and 48 h after administration accounted for 77.5, 95.9, and 96.9% of the dose, respectively. Excretion into feces was fairly low, 0.6% of the dose until 48 h. These findings demonstrate that the absorbed pivalic acid is mostly excreted in the urine. After administration of the 26.6-mg/kg dose, the urinary excretion rate became slower than that after administration of the 6.65-mg/kg dose; thus, the cumulative excretions up to 6, 24, and 72 h were 55.6, 93.1, and 94.6% of the dose, respectively. The fecal excretion until 72 h was 2.4%. The urinary excretion rate for the 532-mg/kg dose became slower, so excretion up to 24 h was only 52.0%. Fecal excretion up to 72 h was 30.8% of the dose. This suggests that the extent of absorption is decreased for the higher dose.
(iv) Metabolic profile in rat urine. Unchanged pivalic acid and three conjugated metabolites (glycine, glucuronic acid, and carnitine conjugates) were detected in dog urine ( Fig. 3  and 4) . A similar metabolic pattern of pivalic acid in rat urine after [pivaloyl-
14 C]S-1108 administration was confirmed by TLC analysis. Then, these concentrations of metabolites and unchanged pivalic acid in rat urine were determined.
As Fig. 6 shows, the glycine conjugate was excreted most abundantly; this was followed by the carnitine conjugate. The glucuronide was excreted the least. Excretion of these metabolites and pivalic acid was rapid, and 75 to 90% of the ultimate amount recovered was excreted during the first 6 h. The excretion of metabolites after administration of the dose of 26.6 mg/kg was similar to that after administration of the dose of 
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6.65 mg/kg except for excretion of pivalic acid, two times more of which was excreted. However, the excretion of these compounds was slower than excretion after administration of the 6.65-mg/kg dose. Up to 48 h after administration of the 532-mg/kg dose, 10.8% of the pivalic acid, 14.6% of the glycine conjugate, 29.3% of the glucuronide, and 5.7% of the carnitine conjugate were excreted. The proportion of metabolites excreted was different from that excreted after administration of the lower doses; i.e., the glucuronide was excreted to the greatest degree, and this was followed by the glycine and carnitine conjugates, while after administration of the lower doses, glucuronide was excreted to the lowest degree. The excretion of these metabolites as well as pivalic acid was slower than that after administration of the lowest dose; thus, excretion until 6 h accounted for only 10 to 20% of the ultimate recovery. Figure 7 shows the concentration of radioactivity in plasma after oral administration of [pivaloyl- 14 C]S-1108 at three doses. The C max s (6.43, 50.69, and 546.5 nmol/ml) increased proportionately after administration of the doses of 6.65 and 26.6 mg/kg but disproportionately after administration of 532 mg/ kg. In comparison with the C max for rats, the C max s for the dogs administered doses of 6.65 and 26.6 mg/kg were similar, but those for the dogs administered the dose of 532 mg/kg were lower. The T max for the dogs administered the dose of 532 mg/kg was 10 h, and that for the dogs administered doses of 6.65 and 26.6 mg/kg was 4 to 8 h. The excretion was significantly later than that in the rats. The elimination of radioactivity from plasma was slower in dogs than in rats for all doses. In dogs, radioactivity was detected in plasma even 144 h after administration.
Disposition of pivalic acid from [pivaloyl-
C]S-1108 in dogs. (i) Concentration in plasma.
The proportion of free pivalic acid was 60 to 90% of the radioactivity in plasma for all doses (data not shown).
(ii) Distribution in tissue. Table 3 provides the concentration of radioactivity in tissue 144 h after oral administration of [pivaloyl- 14 C]S-1108 at three doses. After administration of the dose of 6.65 mg/kg, radioactivity was detected in all tissues and organs. The concentrations in the liver, cortex of the kidney, and skeletal muscle were more than 10 times higher than the concentrations in plasma, but those in the lung, heart, and pancreas were almost similar to those in plasma. Radioactivity remained in the liver, cortex of the kidney, and skeletal muscle at all doses.
(iii) Excretion. Table 4 provides the urinary and fecal excretion of radioactivity after oral administration of [pivaloyl-14 C]S-1108 at three doses.
The urinary excretion in dogs was slower than that in rats, and the cumulative levels of excretion up to 24, 48, and 144 h were 75.3, 82.9, and 88.1% of the dose, respectively, after FIG. 6 . Excretion of radioactivity of free pivalic acid and its metabolites in urine from rats after oral administration of [pivaloyl- 14 C]S-1108. Doses of 6.65 mg/kg (A), 26.6 mg/kg (B), and 532 mg/kg (C) were given. Each point represents the mean Ϯ standard deviation for four rats. E, total; F, pivalic acid; å, pivaloylglycine; s, pivaloylglucuronide; ç, pivaloylcarnitine. administration of the dose of 6.65 mg/kg. Fecal excretion up to 144 h was 7.0% of the dose. After administration of the 26.6-mg/kg dose, the excretion rate shortly after administration was similar to that after administration of the dose of 6.65 mg/kg, but that until 144 h was 76.3%, approximately 10% lower than that after administration of the dose of 6.65 mg/kg. On the other hand, fecal excretion after administration of the 26.6-mg/kg dose was 18.0% of the dose, which was approximately 10% higher than that after administration of the dose of 6.65 mg/kg. The urinary excretion after administration of the dose of 532 mg/kg became slower, so excretion up to 24 h was only 46.5% of the dose. Fecal excretion up to 144 h was 31.4% of the dose. This suggests that the extent of absorption was also decreased at the higher dose in dogs.
(iv) Metabolic profile in dog urine. The concentrations of unchanged pivalic acid and its conjugated metabolites were determined, and Fig. 8 shows the results.
After administration of the 6.65-mg/kg dose, the most abundantly excreted metabolite was the glycine conjugate (37.9% until 144 h); this was followed by the carnitine conjugate (25.9%), and the glucuronic acid conjugate (12.9%). The excretion rate of these compounds was slow, and only 5 to 13% of the ultimate amount recovered was excreted during the first 4 h. After administration of the 26.6-mg/kg dose, the excretion of the glycine and carnitine conjugates was extensive, but that of glucuronide was the lowest. The excretion profile after administration of the 532-mg/kg dose was different from that after administration of the lower doses. Excretion of glucuronide was highest, and that of the glycine and carnitine conjugates was low. The excretion of these conjugates was fairly slow.
DISCUSSION
To elucidate the metabolic fate of pivalic acid generated from S-1108 in the body, [pivaloyl-
14 C]S-1108, labeled at the pivalic acid moiety in the POM side chain, was administered to rats and dogs.
In both rats and dogs most of the radioactive compound absorbed was excreted in the urine. Two radioactive compounds in dog urine given [pivaloyl- 14 C]S-1108 were then confirmed to be pivaloylcarnitine and pivaloylglycine by comparison of their R f values obtained by TLC with those of authentic reference compounds. Pivaloylcarnitine was hydrolyzed under mild alkaline conditions, but pivaloylglycine could not be hydrolyzed under these conditions. The existence of the third conjugated metabolite, pivaloylglucuronide, was proved by ␤-glucuronidase treatment of dog urine. Furthermore, the other conjugate which developed close to pivaloylglucuronide on TLC and which was thought to be ␤-glucuronidase-resistant conjugate was detected. It seemed to be ␤-glucuronidase-resistant glucuronide generated by molecular rearrangement as reported for the ester glucuronides bilirubin (1), clofiblic acid (6), isoxepac (11) , and probenecid (4) .
As for the metabolites of pivalic acid, the formation of the glucuronic acid conjugate in rats and rabbits (3) and that of glucuronic acid and the carnitine conjugate in humans and monkeys (30) were reported, but that of the glycine conjugate has not been reported yet. Thus, in the present study, metabolic production and excretion into urine of the glycine conjugate of pivalic acid was observed by administration of [pivaloyl-
14
C]S-1108 and by comparing its metabolites with those of radiolabeled authentic compounds. Free pivalic acid accounted for most of the radioactivity in plasma following the administration of [pivaloyl- 14 C]S-1108 in both rats and rabbits. There is a great difference in the metabolic profile of pivalic acid between animals and humans; free pivalic acid was hardly found in human plasma (28) .
A profile similar to that described above was shown in rats and dogs, but the elimination of pivalic acid from plasma was apparently different; it disappeared rapidly from rats and slowly from dogs. A similar tendency of the elimination rate of drug from tissue was observed. The elimination of drug from the tissue of dogs was supposed to be slower than that from the tissue of rats. Indeed, slower elimination of pivalic acid from tissues or organs has also been observed in another experiment (5) , in which [ 14 C]sodium pivalate was administered to dogs intravenously and the time course of the levels of pivalic acid in tissue was determined.
The distribution profile was also different between rats and dogs. In rats, almost similar levels of pivalic acid and/or its metabolites were distributed in all tissues and organs, the levels decreased at similar rates, and radioactivity was not retained in any tissues. On the other hand, in dogs, an uneven distribution profile was observed; the levels observed in the liver, kidney, skeletal muscle, and skin were more than 10 times higher than those observed in plasma. The high level of pivalic acid or its related compounds in skeletal muscle may be involved in the skeletal muscle disorder observed in dogs in high-dose toxicity studies (24, 25) .
Almost all of the pivalic acid absorbed was excreted into the urine in rats and dogs, and excretion was finished during the first 24 h in rats, whereas the excretion rate in dogs was slower than that in rats. These phenomena are also likely to be involved in the muscular disorder shown in dogs (24, 25) and somewhat in rats (13, 22) . Quistad et al. (26) also reported that about half of the administered radiolabel was retained in dog muscle as the carnitine conjugate of cyclopropane carboxylic acid, a one-carbon-depleted analog of pivalic acid, following administration of an oral dose of 14 C-labeled hexadecylcyclopropanecarboxylate. Furthermore, they demonstrated that there is a marked difference in the metabolism and distribution of the cyclopropane carboxylic acid left from cyclopropate between dogs and rats and that this is responsible for the greater sensitivity of dogs than rats in subacute toxicology studies with cyclopropate.
As for the urinary metabolites, both rats and dogs excreted three kinds of conjugated metabolites: carnitine, glycine, and glucuronic acid conjugates. The proportion of these metabolites depends on the dose. The metabolic formation of glycine and carnitine conjugates needs acetyl coenzyme A as a cofactor, and that of glucuronic acid conjugate needs uridine diphosphate glucuronic acid (UDPGA). Therefore, the extent of conjugate formation is regulated by the amounts of cofactor that are involved. The concentrations of acetyl coenzyme A and UDPGA in rat liver are reported to be ca. 50 nmol/g (7) and ca. 275 nmol/g (8), respectively. The greater difference in the cofactor concentration might be one of factors that regulates the formation of pivalic acid conjugates, because greater amounts of carnitine and glycine conjugate were observed after administration of the lower doses and greater amounts of glucuronic acid conjugate were found after administration of the highest dose. A part of pivalic acid is excreted as the carnitine conjugate in dogs and rats. The plasma carnitine level in dogs decreased to approximately half the control level in the toxicity study of the oral dose of 400 mg of S-1108 per kg given for 13 weeks, but it returned to the initial level up to 1 week after the cessation of administration (18) . In humans the pivalic acid cleft from POM-containing antibiotics was also excreted as pivaloylcarnitine (9, 10, 15-17, 27, 28, 30) . Holme et al. (9) demonstrated a severe decrease in the serum carnitine level of because of treatment with a mixture of pivampicillin and pivmecillinam in girls given long-term treatment for urinary tract infections. However, Nakashima et al. (21) reported that although the plasma carnitine concentration was reduced to 50 to 70% of the control value throughout an 8-day administration of 200 mg of S-1108 three times a day, it returned to the control value within a few days after the 8-day administration of the dose, and no side effects and no abnormal physical and laboratory test values were observed.
In conclusion, an interspecies difference in the elimination rate of pivalic acid was found between rats and dogs; it was rapid in rats and slow in dogs, and such a difference might affect the difference in the degree of skeletal muscle disorders observed in these animals in long-term toxicity studies. Furthermore, it is suggested that a side effect such as muscle disorders may be unlikely in humans because the pivalic acid left from S-1108 is almost quantitatively conjugated with carnitine in the human body and is excreted rapidly into the urine (21, 28) . The safety of the clinical use of S-1108 given at 200 mg three times a day has been established in phase I clinical studies (21, 27) .
